secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001193125-24-153667
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium reports Phase 2 topline data for EQ101 in alopecia areata; 20% of completers achieved SALT ≤20
--------------------------------------------------------------------------------

- Of 25 completers (baseline SALT 35-100), 20% reached SALT ≤20 at week 24; mean SALT improvement 13.5%.
- In moderate-to-severe subgroup (n=17), 29% achieved SALT ≤20; mean improvement 18.4% from baseline.
- EQ101 well tolerated, no SAEs; 98.9% AEs Grade 1/2; common: URI, headache, fatigue; two Grade 3 events.
- Preliminary PD data show reduction of CD132 on CD8 and NK cells, consistent with target engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524153667/0001193125-24-153667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524153667/d842173d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-153667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer